Current Bladder Dysfunction Reports

, Volume 13, Issue 4, pp 262–266 | Cite as

Weight Loss and Overactive Bladder

  • Christopher Caputo
  • Alexander Uhr
  • Alana MurphyEmail author
Overactive Bladder and Lower Urinary Tract Symptoms (U Lee and S Adelstein, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Overactive Bladder and Lower Urinary Tract Symptoms


Purpose of Review

We sought to explore the relationship between obesity and overactive bladder (OAB) and to review the available literature that supports weight loss as a means to alter OAB severity and bother.

Recent Findings

Over the past 15 years, several population-based human studies and animal models have identified obesity as a risk factor for the development of OAB. The bariatric surgery literature demonstrates that substantial weight loss following some form of gastric bypass can lead to at least subjective improvement in OAB symptoms. Ongoing research seeks to further elucidate the role of anti-inflammatory agents, anti-oxidants, and β3-receptor agonists in obesity-associated OAB.


The currently available literature has identified obesity as a risk factor for the development OAB. Data taken from the bariatric surgery literature indicates that surgical weight loss can lead to a significant improvement in OAB severity and bother. Future studies will determine if less dramatic weight changes can lead to significant and sustained changes in OAB parameters. Based on the available literature, clinicians should start to counsel their obese patients with OAB that weight loss can help improve their OAB severity and bother.


Overactive bladder Obesity Metabolic syndrome Urinary urgency 



Overactive bladder


Urgency urinary incontinence


Basic metabolic index


International Prostate Symptom Score


Overactive Bladder Symptom Score


Stress urinary incontinence


Mixed urinary incontinence


Overactive Bladder Questionnaire Short Form


Brown adipose tissue


Patients’ Perception of Intensity of Urgency Scale




Tumor necrosis factor




Compliance With Ethical Standards

Conflict of Interest

C Caputo: none

A Uhr: none

A Murphy: none


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Toozs-Hobson P, Freeman R, Barber M, Maher C, Haylen B, Athanasiou S, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for reporting outcomes of surgical procedures for pelvic organ prolapse. Neurourol Urodyn. 2012;31(4):415–21.CrossRefGoogle Scholar
  2. 2.
    Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77:1081–7.CrossRefGoogle Scholar
  3. 3.
    Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–14.CrossRefGoogle Scholar
  4. 4.
    Coyne KS, Sexton CC, Bell JA, Thompson CL, Dmochowski R, Bavendam T, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn. 2013;32(3):230–7.CrossRefGoogle Scholar
  5. 5.
    • Richter HE, Whitehead N, Arya L, et al. Genetic contributions to urgency urinary incontinence in women. J Urol. 2015;193:2020–7. Identified association between genetic variants in the ZFP521, CIT, and ADAMTS16 genes and OAB in postmenopausal women. CrossRefGoogle Scholar
  6. 6.
    • Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36. Early study to identify obesity as a risk factor for developing OAB PubMedGoogle Scholar
  7. 7.
    Zacche MM, Giarenis I, Thiagamoorthy G, Robinson D, Cardozo L. Is there an association between aspects of metabolic syndrome and overactive bladder? A prospective cohort study in women with lower urinary tract symptoms. Eur J Obstet Gynecol Reprod Biol. 2017;217:1–5.CrossRefGoogle Scholar
  8. 8.
    Kim JH, Sun HY, Park SY, Soh MJ, Kim YJ, Song YS. Association between obesity and lower urinary tract symptoms: propensity score matching study between healthy controls and obese patients seeking bariatric surgery. Surg Obes Relat Dis. 2016;12:1585–93.CrossRefGoogle Scholar
  9. 9.
    He Q, Babcook MA, Shukla S, Shankar E, Wang Z, Liu G, et al. Obesity-initiated metabolic syndrome promotes urinary voiding dysfunction in mouse models. Prostate. 2016;76(11):964–76.CrossRefGoogle Scholar
  10. 10.
    Subak LL, Wing R, Smith West D, et al. Weight loss to treat urinary incontinence in overweight and obese women. New Engl J Med. 2009;360(5):481–90.CrossRefGoogle Scholar
  11. 11.
    Auwad W, Steggles P, Bombieri L, Waterfield M, Wilkin T, Freeman R. Moderate weight loss in obese women with urinary incontinence: a prospective longitudinal study. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(9):1251–9.CrossRefGoogle Scholar
  12. 12.
    •• O’Boyle CJ, O’Sullivan OE, Shabana H, et al. The effect of bariatric surgery on urinary incontinence in women. Obes Surg. 2016;26:1471–8. Study followed 108 women undergoing bariatric surgery. After a mean weight loss of 16 kg/m 2 , 7 women with urgency incontinence (53%) and 12 women with mixed incontinence (32%) experienced a subjective cure in their incontinence. CrossRefGoogle Scholar
  13. 13.
    •• Kim JH, Sun HY, Lee HY, et al. Improvement of voiding characteristics in morbidly obese women after bariatric surgery: a single-center study with 1 year follow up. Surg Obes Rel Dis. 2017;13:836–41. Study followed 57 women undergoing bariatric surgery. After 1 year of follow-up and a mean weight loss of 9.5 kg/m 2 , the women reported a significant improvement in OAB Symptom Scores. CrossRefGoogle Scholar
  14. 14.
    •• Palleschi G, Pastore AL, Rizzello M, et al. Laparoscopic sleeve gastrectomy effects on overactive bladder symptoms. J Surg Res. 2015;196:307–12. Study followed 120 men and women undergoing bariatric surgery and compared them to 120 obese men and women waiting to undergo bariatric surgery. Surgical patients demonstrated significant improvement in OAB questionnaire Short Form scores compared to no significant change for non-surgical patients. CrossRefGoogle Scholar
  15. 15.
    Townsend K, Tseng YH. Brown adipose tissue: recent insights into development, metabolic function and therapeutic potential. Adipocyte. 2012;1(1):13–24.CrossRefGoogle Scholar
  16. 16.
    Cawthorne MA, Sennitt MV, Arch JR, Smith SA. BRL 35135, a potent and selective atypical beta-adrenoceptor agonist. Am J Clin Nutr. 1992;55(Suppl):252S–7S.CrossRefGoogle Scholar
  17. 17.
    Hong S, Song W, Zushin PH, et al. Phosphorylation of beta-3 adrenergic receptor at serine 247 by ERK MAP kinase drives lipolysis in obese adipocytes. Mol Metab. 2018;12:25–38.CrossRefGoogle Scholar
  18. 18.
    Cypess AM, Weiner LS, Roberts-Toler C, Elía EF, Kessler SH, Kahn PA, et al. Activation of human Brown adipose tissue by a beta3-adrenergic receptor agonist. Cell Metab. 2015;21(1):33–8.CrossRefGoogle Scholar
  19. 19.
    Chapple CR, Dvorak V, Radziszewski P, et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J. 2013;24(9):1447–58.CrossRefGoogle Scholar
  20. 20.
    Krhut J, Martan A, Zachoval R, et al. Impact of body mass index on treatment efficacy of mirabegron for overactive bladder in females. Eur J Obstet Gynecol Reprod Biol. 2015;196:64–8.CrossRefGoogle Scholar
  21. 21.
    Wellen KE, Hotamisligil GS. Obesity-induced infammatory changes in adipose tissue. J Clin Investig. 2003;112(12):1785–8.CrossRefGoogle Scholar
  22. 22.
    Haldar S, Dru C, Choudhury D, Mishra R, Fernandez A, Biondi S, et al. Inflammation and pyroptosis mediate muscle expansion in an interleukin-1beta (IL-1beta)-dependent manner. J Biol Chem. 2015;290(10):6574–83.CrossRefGoogle Scholar
  23. 23.
    Bouchelouche K, Alvarez S, Horn T, Nordling J, Bouchelouche P. Human detrusor smooth muscle cells release interleukin-6, interleukin-8, and RANTES in response to proinflammatory cytokines interleukin-1β and tumor necrosis factor-α. Urology. 2006;67(1):214–9.CrossRefGoogle Scholar
  24. 24.
    Ding H, Li N, He X, Liu B, Dong L, Liu Y. Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast. Int Urol Nephrol. 2017;49:1723–30.CrossRefGoogle Scholar
  25. 25.
    Baile CA, Yang JY, Rayalam S, Hartzell DL, Lai CY, Andersen C, et al. Effect of resveratrol on fat mobilization. Ann N Y Acad Sci. 2011;1215:40–7.CrossRefGoogle Scholar
  26. 26.
    Alexandre EC, Calmasini FB, de Oliveira MG, Silva FH, da Silva CPV, André DM, et al. Chronic treatment with resveratrol improves overactive bladder in obese mice via antioxidant activity. Euro J Pharm. 2016;788:29–36.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Christopher Caputo
    • 1
  • Alexander Uhr
    • 1
  • Alana Murphy
    • 1
    Email author
  1. 1.Department of UrologyThomas Jefferson University HospitalPhiladelphiaUSA

Personalised recommendations